Tocilizumab Assessed for JIA-Associated Uveitis

This article originally appeared here.
Rapid, maintained improvement in ocular parameters for JIA-linked uveitis refractory to anti-TNF tx
Rapid, maintained improvement in ocular parameters for JIA-linked uveitis refractory to anti-TNF tx

HealthDay News — For patients with juvenile idiopathic arthritis (JIA)-associated uveitis refractory to anti-tumor necrosis factor (TNF) therapy, tocilizumab (TCZ) is beneficial, yielding improvement in all ocular parameters, according to a study published in the March issue of Arthritis & Rheumatology.

Vanesa Calvo-Río, MD, PhD, from the Hospital Universitario Marqués de Valdecilla in Santander, Spain, and colleagues conducted a multicenter trial involving 25 patients with JIA-associated uveitis that was refractory to conventional immunosuppressive drugs and anti-TNF agents. In 22 of the patients, uveitis was bilateral, with 47 affected eyes. 

Related Articles

The researchers found that in most cases, patients received 8mg/kg TCZ intravenously every four weeks. Rapid and maintained improvement in all ocular parameters was seen with TCZ treatment. Overall, 79.2 and 88.2% of patients showed improvement in anterior chamber cell number after six months and one year, respectively. In patients with cystoid macular edema there was a decrease in central macular thickness measured by optical coherence tomography from a mean of 401.7 ± 86.8 µm to 259.1 ± 39.5 µm after six months of TCZ (P=0.012). There was an increase in the best corrected visual acuity from 0.56 ± 0.35 to 0.64 ± 0.32 (P<0.01). Visual improvement persisted after a median follow-up of 12 months, and complete remission of uveitis was seen in 19 of 25 patients.

"TCZ appears to be a useful therapy for severe refractory JIA-associated uveitis," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)